EUVIMEDEUVIMED entdecken
Open Access

Medicare Advantage Enrollment Following the 21st Century Cures Act in Adults With End-Stage Renal Disease

Kevin H Nguyen, Eunhae G Oh, David J Meyers, Maricruz Rivera-Hernandez, Daeho Kim, Rajnish Mehrotra, Amal N Trivedi

JAMA Network Open · 2024

DOI: 10.1001/jamanetworkopen.2024.32772 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2024. Verfasst von Kevin H Nguyen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Law, Policy, and Management, Boston University School of Public Health, Boston, Massachusetts. Hauptthemen laut MEDLINE: Kidney Failure, Chronic, Medicare Part C. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIA NIH HHS, NIMHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance In January 2021, under the 21st Century Cures Act, Medicare beneficiaries with end-stage renal disease (ESRD) were permitted to enroll in private Medicare Advantage (MA) plans for the first time. In the first year of the Cures Act, there was a 51% increase in MA enrollment among beneficiaries with ESRD.

Objective

To examine changes in MA enrollment among Medicare beneficiaries with ESRD in the first 2 years of the Cures Act and, among beneficiaries newly enrolled in MA in 2021, to assess the proportion of beneficiaries who switched MA contracts and how the characteristics of contracts changed. Design, Setting, and Participants This cross-sectional, population-based time-trend study was conducted from January 2020 to December 2022. Eligible participants included Medicare beneficiaries with ESRD. Data analysis was conducted from August 2023 to March 2024. Exposure Enrollment in Medicare during the first 2 years of the 21st Century Cures Act. Main Outcomes and Measures The primary outcomes were enrollment in MA, switching between traditional Medicare (TM) and MA, and switching between MA contracts from 2021 to 2022.

Results

There were 718 252 unique Medicare beneficiaries with ESRD between 2020 and 2022 (1 659 652 beneficiary-years). In 2022, there were 583 203 beneficiaries with ESRD (mean [SD] age, 64.9 [14.1] years, 245 153 female (42.0%); 197 988 Black [34.0%]; 47 912 Hispanic [8.2%]). The proportion of beneficiaries with ESRD who were enrolled in MA increased from 25.1% (118 601 of 472 234 beneficiaries) in January 2020 to 43.1% (211 896 of 491 611 beneficiaries) in December 2022. Increases in MA enrollment were larger in the first year of the Cures Act (12.6 percentage points [pp]; 95% CI 12.3-12.8 pp) compared with the second year (5.7 pp; 95% CI, 5.5-5.9 pp). Changes between December 2020 and December 2022 ranged between 49.3% for Asian or Pacific Islander beneficiaries (difference = 13.0 pp; 95% CI, 12.2-13.8 pp) and 207.2% for American Indian or Alaska Native beneficiaries (difference = 17.0 pp; 95% CI, 15.3-18.7 pp). Changes were high among partial dual-eligible (difference = 35.5 pp; 95% CI, 34.9-36.1 pp; 134.7% increase) and fully dual-eligible beneficiaries (difference = 22.8 pp, 95% CI, 22.5-23.1 pp; 98.0% increase). Among 53 366 beneficiaries enrolled in MA in 2021, 37 439 (70.2%) remained in their contract, 11 730 (22.0%) switched contracts, and 4197 (7.9%) switched to TM in 2022. Compared with the characteristics of MA enrollees with ESRD in 2021, those in 2022 were more likely to be in contracts with lower premiums and with a rating of 4.5 stars or higher. Conclusions and Relevance In this cross-sectional time-trend study of Medicare beneficiaries with ESRD, MA enrollment continued to increase in the second year of the Cures Act, particularly among racially or ethnically minoritized individuals and dual eligible populations. These findings suggest need to monitor the equity of care for beneficiaries with ESRD as they enroll in managed care plans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney Failure, ChronicMedicare Part CHumansUnited StatesFemaleMaleAgedCross-Sectional StudiesMiddle AgedAged, 80 and over

Autor:innen und Institutionen

  • Department of Health Law, Policy, and Management, Boston University School of Public Health, Boston, Massachusetts.
  • Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence Rhode Island.
  • Now with Medicare Payment Advisory Commission, Washington DC.
  • Kidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington, Seattle.
  • Providence VA Medical Center, Providence, Rhode Island.

Förderung

  • NIDDK NIH HHS
  • NIA NIH HHS
  • NIMHD NIH HHS

Zitieren

APA

Nguyen, K. H., Oh, E. G., Meyers, D. J., Rivera-Hernandez, M., Kim, D., Mehrotra, R., & Trivedi, A. N. (2024). Medicare Advantage Enrollment Following the 21st Century Cures Act in Adults With End-Stage Renal Disease. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.32772

Vancouver

Nguyen KH, Oh EG, Meyers DJ, Rivera-Hernandez M, Kim D, Mehrotra R, et al. Medicare Advantage Enrollment Following the 21st Century Cures Act in Adults With End-Stage Renal Disease. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.32772

BibTeX
@article{Nguyen2024,
  author = {Nguyen, Kevin H and Oh, Eunhae G and Meyers, David J and Rivera-Hernandez, Maricruz and Kim, Daeho and Mehrotra, Rajnish and Trivedi, Amal N},
  title = {Medicare Advantage Enrollment Following the 21st Century Cures Act in Adults With End-Stage Renal Disease},
  journal = {JAMA Network Open},
  year = {2024},
  doi = {10.1001/jamanetworkopen.2024.32772}
}
Kostenlos starten →